Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Cyclohexane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane SCHEMBL744131 | 0.95 | ALDH1A1 (0.67) | ALDH1A1LMNATSHRTDP1TP53 | |
| Cyclopentane SCHEMBL9633785 | 0.95 | — | — | |
| Isopropyl Alcohol SCHEMBL782162 | 0.95 | — | — | |
| Cyclohexane SCHEMBL9221107 | 0.90 | ALDH1A1 (0.60) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL27448530 | 0.84 | — | — | |
| Isopropyl Alcohol SCHEMBL1236799 | 0.84 | ALDH1A1 (0.86) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL27381930 | 0.84 | ALDH1A1 (0.86) | ALDH1A1LMNATSHRTDP1TP53 | |
| Isopropyl Alcohol SCHEMBL9317726 | 0.84 | — | — | |
| Isopropyl Alcohol SCHEMBL150260 | 0.84 | — | — | |
| Cyclohexane SCHEMBL29188796 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115057756-A | Method for separating cyclohexane-isopropanol-water by pervaporation extraction rectification process | 青岛科技大学 | 2022-09-16 | — | — | CN | claimed |
| CN-116236816-A | Composite sieve plate extraction tower and application thereof in low interfacial tension extraction system | 浙江大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-115057756-A | Method for separating cyclohexane-isopropanol-water by pervaporation extraction rectification process | 青岛科技大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-115057756-A | Method for separating cyclohexane-isopropanol-water by pervaporation extraction rectification process | 青岛科技大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-115057756-A | Method for separating cyclohexane-isopropanol-water by pervaporation extraction rectification process | 青岛科技大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-114456039-A | Partition wall tower type isopropanol solution molecular sieve membrane distillation separation and purification method | 浙江天采云集科技股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114292165-A | Partition wall tower type isopropanol solution adsorption, rectification, separation and purification method | 四川天采科技有限责任公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11046979-B2 | Recombinant algal microorganisms having increased lipid production, and methods of making and using the same | SYNTHETIC GENOMICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210163457-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | HANGZHOU SOLIPHARMA CO., LTD. (CN) | 2021-06-03 | — | — | US | disclosed |
| EP-3827080-A1 | MICROORGANISMS HAVING INCREASED LIPID PRODUCTION, AND COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Synthetic Genomics, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20170145000-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2017-05-25 | — | — | US | disclosed |
| EP-1544198-B1 | A process for the preparation of crystalline losartan potassium | DIPHARMA SPA (IT) | 2008-06-04 | — | — | EP | disclosed |
| EP-1544198-A1 | A process for the preparation of crystalline losartan potassium | Dipharma S.p.A. (IT) | 2005-06-22 | — | — | EP | disclosed |
| US-20050131040-A1 | Process for the preparation of crystalline losartan potassium | DIPHARMA S.P.A. (IT) | 2005-06-16 | — | — | US | disclosed |
| EP-1363893-A1 | PROCESS FOR PURIFICATION OF WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070503-A1 | PROCESS FOR PURIFICATION OF WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-4076756-A | Process for the preparation of triarylborane | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4046815-A | Process for the preparation of triarylborane | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
| US-4045495-A | Process for the preparation of triarylboranes | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-08-30 | — | — | US | disclosed |
| US-3998800-A | USING A NONPOLAR HYDROCARBON, AN ALCOHOL AND WATER | THE PROCTER & GAMBLE COMPANY (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145000-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | SLC5A2, SLC5A1, GCG | ALDH1A1 2379/4885LMNA 2730/4885TSHR 4311/4885 |
| US-20210163457-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | SLC5A2, SLC5A1, GCG | ALDH1A1 2379/4885LMNA 2730/4885TSHR 4311/4885 |
| US-20050131040-A1 | Process for the preparation of crystalline losartan potassium | REN, AGT, ACE | ALDH1A1 1488/4885LMNA 241/4885TSHR 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.